Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

277.87USD
22 Mar 2017
Change (% chg)

$2.08 (+0.75%)
Prev Close
$275.79
Open
$276.43
Day's High
$278.54
Day's Low
$274.93
Volume
1,333,588
Avg. Vol
1,823,764
52-wk High
$333.65
52-wk Low
$223.02

BIIB.O

Chart for BIIB.O

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $59,557.39
Shares Outstanding(Mil.): 215.95
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 16.31 29.30 30.07
EPS (TTM): 16.91 -- --
ROI: 20.31 13.52 13.05
ROE: 34.42 14.43 14.20

Biogen wins ruling in Tecfidera IP case; shares rise

NEW YORK Biogen Inc on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down.

5:03pm EDT

Biogen wins ruling in Tecfidera IP case; shares rise

NEW YORK Biogen Inc on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down.

Mar 21 2017

Biogen wins ruling in Tecfidera IP case; shares rise

NEW YORK, March 21 Biogen Inc on Tuesday won an intellectual property rights ruling against hedge fund manager Kyle Bass over its top multiple sclerosis pill, Tecfidera, pushing shares up more than 1 percent on a day when most U.S. stocks were down.

Mar 21 2017

Israel's BrainStorm names Biogen senior executive Kern as COO

TEL AVIV Israel's BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer.

Mar 06 2017

Israel's BrainStorm names Biogen senior executive Kern as COO

TEL AVIV, March 6 Israel's BrainStorm Cell Therapeutics, which is developing an adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), on Monday named Ralph Kern as chief operating officer.

Mar 06 2017

BRIEF-Forward Pharma receives $1.25 bln pursuant to settlement and license agreement with Biogen

* Forward Pharma received US$ 1.25 bln pursuant to settlement and license agreement with Biogen

Feb 09 2017

BRIEF-Forward Pharma enters license agreement with 2 units of Biogen and other parties

* Approved entry into settlement, license agreement with 2 wholly owned subsidiaries of Biogen Inc and certain other parties

Feb 01 2017

BRIEF-Biogen completes separation of global hemophilia business, Bioverativ

* Biogen completes separation of global hemophilia business, bioverativ Source text for Eikon: Further company coverage:

Feb 01 2017

Biogen sees gradual Spinraza launch, eyes mid-year EU approval

Biogen Inc said on Thursday that the first U.S. patients have received its new drug for the leading genetic cause of death in infants and that it anticipates mid-year approval of Spinraza in the European Union.

Jan 26 2017

UPDATE 3-Biogen sees gradual Spinraza launch, eyes mid-year EU approval

Jan 26 Biogen Inc said on Thursday that the first U.S. patients have received its new drug for the leading genetic cause of death in infants and that it anticipates mid-year approval of Spinraza in the European Union.

Jan 26 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $126.26 -0.99
Pfizer Inc. (PFE.N) $34.47 +0.22
Novartis AG (NOVN.S) CHF73.40 -1.05
Merck & Co., Inc. (MRK.N) $63.50 -0.41
Roche Holding Ltd. (ROG.S) CHF250.20 +0.10
Roche Holding Ltd. (RO.S) CHF250.50 -0.25
Bayer AG (BAYGn.DE) €105.05 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.77 +0.05
GlaxoSmithKline plc (GSK.L) 1,670.50 -10.00

Earnings vs. Estimates